Membrane Plasmalogen Composition and Cellular Cholesterol Regulation: a Structure Activity Study

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2010 Jun 16

PMID 20546600

Citations 33

Authors

Rishikesh Mankidy

Pearson Wk Ahiahonu

Hong Ma

Dushmanthi Jayasinghe

Shawn A Ritchie

Mohamed A Khan

Khine K Su-Myat

Paul L Wood

Dayan B Goodenowe

Affiliations

Soon will be listed here.

Abstract

Background: Disrupted cholesterol regulation leading to increased circulating and membrane cholesterol levels is implicated in many age-related chronic diseases such as cardiovascular disease (CVD), Alzheimer's disease (AD), and cancer. In vitro and ex vivo cellular plasmalogen deficiency models have been shown to exhibit impaired intra- and extra-cellular processing of cholesterol. Furthermore, depleted brain plasmalogens have been implicated in AD and serum plasmalogen deficiencies have been linked to AD, CVD, and cancer.

Results: Using plasmalogen deficient (NRel-4) and plasmalogen sufficient (HEK293) cells we investigated the effect of species-dependent plasmalogen restoration/augmentation on membrane cholesterol processing. The results of these studies indicate that the esterification of cholesterol is dependent upon the amount of polyunsaturated fatty acid (PUFA)-containing ethanolamine plasmalogen (PlsEtn) present in the membrane. We further elucidate that the concentration-dependent increase in esterified cholesterol observed with PUFA-PlsEtn was due to a concentration-dependent increase in sterol-O-acyltransferase-1 (SOAT1) levels, an observation not reproduced by 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibition.

Conclusion: The present study describes a novel mechanism of cholesterol regulation that is consistent with clinical and epidemiological studies of cholesterol, aging and disease. Specifically, the present study describes how selective membrane PUFA-PlsEtn enhancement can be achieved using 1-alkyl-2-PUFA glycerols and through this action reduce levels of total and free cholesterol in cells.

Citing Articles

Mid-life anti-inflammatory metabolites are inversely associated with long-term cardiovascular disease events.

Saeed A, McKennan C, Duan J, Yang Y, Kip K, Finegold D EBioMedicine. 2025; 112:105551.

PMID: 39793479 PMC: 11764641. DOI: 10.1016/j.ebiom.2024.105551.

Low-input lipidomics reveals lipid metabolism remodelling during early mammalian embryo development.

Zhang L, Zhao J, Lam S, Chen L, Gao Y, Wang W Nat Cell Biol. 2024; 26(2):278-293.

PMID: 38302721 DOI: 10.1038/s41556-023-01341-3.

Transient Ca entry by plasmalogen-mediated activation of receptor potential cation channel promotes AMPK activity.

Honsho M, Mawatari S, Fujino T Front Mol Biosci. 2022; 9:1008626.

PMID: 36406270 PMC: 9672372. DOI: 10.3389/fmolb.2022.1008626.

Brain ethanolamine phospholipids, neuropathology and cognition: A comparative post-mortem analysis of structurally specific plasmalogen and phosphatidyl species.

Goodenowe D, Senanayake V Front Cell Dev Biol. 2022; 10:866156.

PMID: 36092723 PMC: 9451657. DOI: 10.3389/fcell.2022.866156.

Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons.

Goodenowe D, Haroon J, Kling M, Zielinski M, Mahdavi K, Habelhah B Front Cell Dev Biol. 2022; 10:864842.

PMID: 35874835 PMC: 9297104. DOI: 10.3389/fcell.2022.864842.

References

Meuwese M, de Groot E, Duivenvoorden R, Trip M, Ose L, Maritz F . ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009; 301(11):1131-9. DOI: 10.1001/jama.301.11.1131. View

Heymans H, Schutgens R, Tan R, van den Bosch H, Borst P . Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome). Nature. 1983; 306(5938):69-70. DOI: 10.1038/306069a0. View

Rapport M, FRANZL R . The structure of plasmalogens. III. The nature and significance of the aldehydogenic linkage. J Neurochem. 1957; 1(4):303-10. DOI: 10.1111/j.1471-4159.1957.tb12086.x. View

Glaser P, Gross R . Rapid plasmenylethanolamine-selective fusion of membrane bilayers catalyzed by an isoform of glyceraldehyde-3-phosphate dehydrogenase: discrimination between glycolytic and fusogenic roles of individual isoforms. Biochemistry. 1995; 34(38):12193-203. DOI: 10.1021/bi00038a013. View

Maeba R, Maeda T, Kinoshita M, Takao K, Takenaka H, Kusano J . Plasmalogens in human serum positively correlate with high- density lipoprotein and decrease with aging. J Atheroscler Thromb. 2007; 14(1):12-8. DOI: 10.5551/jat.14.12. View

Schedin S, SINDELAR P, PENTCHEV P, BRUNK U, Dallner G . Peroxisomal impairment in Niemann-Pick type C disease. J Biol Chem. 1997; 272(10):6245-51. DOI: 10.1074/jbc.272.10.6245. View

Fowler S, Kelly M, Ruh D, Johnson-Wells D . Management of lipid disorders for stroke prevention. J Neurosci Nurs. 2006; 38(4 Suppl):282-7, 295. DOI: 10.1097/01376517-200609000-00003. View

Engelmann B, Streich S, Schonthier U, Richter W, DUHM J . Changes of membrane phospholipid composition of human erythrocytes in hyperlipidemias. I. Increased phosphatidylcholine and reduced sphingomyelin in patients with elevated levels of triacylglycerol-rich lipoproteins. Biochim Biophys Acta. 1992; 1165(1):32-7. DOI: 10.1016/0005-2760(92)90072-4. View

Guan Z, Wang Y, Cairns N, Lantos P, Dallner G, SINDELAR P . Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol. 1999; 58(7):740-7. DOI: 10.1097/00005072-199907000-00008. View

10.

Deshmukh D, Vorbrodt A, Lee P, Bear W, Kuizon S . Studies on the submicrosomal fractions of bovine oligodendroglia: lipid composition and glycolipid biosynthesis. Neurochem Res. 1988; 13(6):571-82. DOI: 10.1007/BF00973300. View

11.

Engelmann B, Brautigam C, Thiery J . Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. Biochem Biophys Res Commun. 1994; 204(3):1235-42. DOI: 10.1006/bbrc.1994.2595. View

12.

Hill S, McQueen M . Reverse cholesterol transport--a review of the process and its clinical implications. Clin Biochem. 1997; 30(7):517-25. DOI: 10.1016/s0009-9120(97)00098-2. View

13.

Lange Y, Strebel F, Steck T . Role of the plasma membrane in cholesterol esterification in rat hepatoma cells. J Biol Chem. 1993; 268(19):13838-43. View

14.

Muzio G, Martinasso G, Trombetta A, Di Simone D, Canuto R, Maggiora M . HMG-CoA reductase and PPARalpha are involved in clofibrate-induced apoptosis in human keratinocytes. Apoptosis. 2006; 11(2):265-75. DOI: 10.1007/s10495-006-3559-y. View

15.

Munn N, Arnio E, Liu D, Zoeller R, Liscum L . Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res. 2003; 44(1):182-92. DOI: 10.1194/jlr.m200363-jlr200. View

16.

Han X, Holtzman D, McKeel Jr D . Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem. 2001; 77(4):1168-80. DOI: 10.1046/j.1471-4159.2001.00332.x. View

17.

Flint O, Masters B, GREGG R, Durham S . HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997; 145(1):99-110. DOI: 10.1006/taap.1997.8174. View

18.

Brosche T, Platt D . The biological significance of plasmalogens in defense against oxidative damage. Exp Gerontol. 1998; 33(5):363-9. DOI: 10.1016/s0531-5565(98)00014-x. View

19.

Ford D, Hale C . Plasmalogen and anionic phospholipid dependence of the cardiac sarcolemmal sodium-calcium exchanger. FEBS Lett. 1996; 394(1):99-102. DOI: 10.1016/0014-5793(96)00930-1. View

20.

Rouser G, Yamamoto A . Curvilinear regression course of human brain lipid composition changes with age. Lipids. 1968; 3(3):284-7. DOI: 10.1007/BF02531202. View